Newsletters

Newsletters

Fall 2018 Newsletter

TransPharm hit a major milestone in September! We have now performed over one thousand preclinical studies since opening in 2008. The team will be celebrating by going out to lunch at a local restaurant.

read more

Summer 2018 Newsletter

We’re not mousing around…TransPharm now has a blog! Stay up-to-date on the latest in microbiology, infectious disease, and antimicrobial resistance with original posts from our in-house scientific writer.

read more

Spring 2018 Newsletter

Although TransPharm is best known for our animal models of infectious disease, we have recently had more requests for our in vitro services. We’d like to take this chance to remind you of what we have to offer outside the vivarium. Our team has experience performing a range of antimicrobial susceptibility testing, including time-kill kinetics assays, checkerboard analyses, minimum bactericidal concentration (MBC) testing, and multiple methods of minimum inhibitory concentration (MIC) testing. Contact us today for a complimentary consultation or to request a free, no-obligation quote!

read more

Winter 2018 Newsletter

The Super Bowl may be over, but our team is always training to compete against Super Bugs! Super bugs, or multi-drug resistant bacteria, are bacteria that cannot be killed using two or more antibiotics. Any species of bacteria can become a super bug, and misusing antibiotics is the leading factor contributing to this growing problem. A 2015 White House Report identified several super bug threats, many of which we use in our research here at TransPharm. We have validated studies using carbapenem-resistant Enterobacteriaceae (CRE), methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. diff), Acinetobacter, and many other super bugs. Have a question about which pathogens and models we specialize in? Contact us at your convenience. There are no half-time shows here; we work around the clock to complete studies for our fans. We don’t have turf or a stadium, but we pride ourselves on being champions in our field for the past 10 years. Several of our clients have published data on novel therapeutics to combat super bugs, and we think that’s something worth cheering for.

read more

Fall 2017 Newsletter

TransPharm has added a new animal model of induced chronic osteomyelitis (bone infection). Osteomyelitis results in pain, loss of mobility, and significant morbidity. Current treatment requires prolonged antibiotic therapy and surgical debridement of sequestra (dead bone). Due to poor drug penetration into the bone and an increase in antibiotic-resistant bacteria, there is an urgent need for novel therapeutics. Our model serves as a screening tool to identify which antimicrobials are most clinically efficacious. Animals are challenged via injection into the cancellous bone marrow through the anterior surface of the proximal tibia. The infection is allowed to incubate for up to 4 weeks before the tibia is harvested for CFU enumeration. The induced chronic osteomyelitis model is currently available for S. aureus and S. epidermidis infections in Sprague-Dawley rats. Additional validations are available upon request.

read more

Contact Us

13 + 4 =

science exchange logo

scientist.com logo

Jackson Certified
Brooklyn-Irish Hills Chamber of Commerce logo